Comparison of human lymphoproliferative and chemotactic responses to S-Ag peptide fragments
Human peptide/protein . | Peptide sequence . | Lymphoproliferative response in patients* . | Lymphoproliferative response in controls . | Chemotaxis . |
|---|---|---|---|---|
| S-Ag | — | ± | ± | + |
| 1-20 | MAASGKTSKSEPNHVIFKKI | — | — | + |
| 11-30 | EPNHVIFKKISRDKSVTIYL | ± | — | + |
| 41-60 | QVQPVDGVVLVDPDLVKGKK | — | — | + |
| 121-140 | PFLLTFPDYLPCSVMLQPAP | + | + | + |
| 131-150 | PCSVMLQPAPQDSGKSCGVD | ±† | — | + |
| 141-160 | QDSGKSCGVDFEVKAFATDS | — | — | — |
| 151-170 | FEVKAFATDSTDAEEDKIPK | — | — | — |
| 161-180 | TDAEEDKIPKKSSVRYLIRS | ±‡ | — | — |
| 171-190 | KSSVRYLIRSVQHAPLEMGP | ±‡ | — | — |
| IRBP | — | ± | — | + |
Human peptide/protein . | Peptide sequence . | Lymphoproliferative response in patients* . | Lymphoproliferative response in controls . | Chemotaxis . |
|---|---|---|---|---|
| S-Ag | — | ± | ± | + |
| 1-20 | MAASGKTSKSEPNHVIFKKI | — | — | + |
| 11-30 | EPNHVIFKKISRDKSVTIYL | ± | — | + |
| 41-60 | QVQPVDGVVLVDPDLVKGKK | — | — | + |
| 121-140 | PFLLTFPDYLPCSVMLQPAP | + | + | + |
| 131-150 | PCSVMLQPAPQDSGKSCGVD | ±† | — | + |
| 141-160 | QDSGKSCGVDFEVKAFATDS | — | — | — |
| 151-170 | FEVKAFATDSTDAEEDKIPK | — | — | — |
| 161-180 | TDAEEDKIPKKSSVRYLIRS | ±‡ | — | — |
| 171-190 | KSSVRYLIRSVQHAPLEMGP | ±‡ | — | — |
| IRBP | — | ± | — | + |
Data compiled from de Smet et al.3,17
± indicates 25%-49% of individuals showed a 2-fold increase in lymphocyte proliferation to ≥ 50 μg/mL of peptide or protein; —, no response observed; and +, 50% or more individuals showed a 2-fold increase in lymphocyte proliferation to ≥ 50 μg/mL of peptide or protein.
Individuals diagnosed with Behçet disease, sarcoidosis, or Vogt Koyanagi Harada disease
Individuals diagnosed with Behçet disease, sarcoidosis only
Individuals diagnosed with Behçet disease only